Life-saving vaccine developed at University of Houston heads to human clinical trials
green light
Fentanyl kills nearly 200 Americans each day, but Houston researchers have developed a vaccine to prevent users from succumbing to an overdose.
Last week, a New York-based startup, OVAX Incorporated, announced that it has licensed that intellectual property and $10 million to commercialize that research.
The discovery of the vaccine comes out of the University of Houston lab of Colin Haile, a research associate professor of psychology at UH and the Texas Institute for Measurement, Evaluation and Statistics (TIMES), as well as a founding member of the UH Drug Discovery Institute. The vaccine will be marketed under the name Fentanyl Armour.
“We believe Fentanyl Armour could have a significant impact on a very serious problem plaguing society for years – opioid misuse,” says Haile, who serves as scientific co-founder and adviser at OVAX, in a press release.
Human trials are set to start as soon as the beginning of 2025.
“This breakthrough discovery could have major implications for the nation’s opioid epidemic by becoming a relapse prevention agent for people trying to quit using opioids,” adds Haile.
In fact, 80 percent of patients with opioid use disorder (OUD) will eventually relapse. Fentanyl Armour could become a landmark addition to our country’s fight against addiction.
- University of Houston plans to build new central campus innovation hub ›
- University of Houston doubles down on Sugar Land tech campus with $65M building ›
- New research lab opens in University of Houston's tech transfer facility ›
- University of Houston reveals $35M campus transformation ahead of centennial ›
- UH lab using mixed reality to optimize designs for the Moon and Mars ›
- University of Houston, Intel team up to prepare workforce for AI revolution ›
- Houston professor earned $500,000 grant to tap into digital twin tech for bridge safety ›
- University of Houston introduces institute to bring business solutions to health care industry ›